ReviewInnere Medizin (Heidelberg, Germany)2025
[What is certain in the treatment of interstitial lung diseases?]
Review in Innere Medizin (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to the wide range of interstitial lung diseases (ILD) with varying prognoses, accurate diagnosis and identification of the underlying cause are essential in patients with ILD to enable targeted therapy. In approximately 50% of cases, an underlying cause can be identified [1]. Once the trigger has been successfully determined, avoidance or elimination of the causative agent represents the key therapeutic intervention. If no identifiable or removable cause can be found, or if exposure cessation alone does not lead to recovery, further treatment follows principles similar to those applied in ILDs of unknown etiology. In this context, distinguishing between inflammatory and fibrotic processes is often challenging [2]. Depending on the disease course, anti-inflammatory and/or antifibrotic therapy may be indicated [3].
Indexed as
Identifiers
41094272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.